Predictive Markers Useful In The Treatment Of Fragile X Syndrome (fxs)


The invention is directed to the use of biomarkers to determine responsiveness of an individual with Fragile X Syndrome (FXS) to treatment with an mGluR5 antagonist.

Download PDF
Document Preview
Document History
  • Publication: Nov 3, 2011
  • Application: Apr 28, 2011
    WO US 2011/0034244 W
  • Priority: Sep 1, 2010
    US US 37919710 P
  • Priority: Apr 30, 2010
    US US 33029910 P

Download Citation

Sign in to the Lens